Dextran 40 and Moxetumomab pasudotox-tdfk Intravenous
Determining the interaction of Dextran 40 and Moxetumomab pasudotox-tdfk Intravenous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: dextran, low molecular weight
Brand name: LMD
Synonyms: n.a.
Generic Name: moxetumomab pasudotox
Brand name: Lumoxiti
Synonyms: Moxetumomab pasudotox, Moxetumomab Pasudotox
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dextran 40-Moxifloxacin
- Dextran 40-Moxifloxacin (Systemic)
- Dextran 40-Moxifloxacin Hydrochloride
- Dextran 40-Moxifloxacin Injection
- Dextran 40-Moxifloxacin Intravenous
- Dextran 40-Moxifloxacin Tablets
- Moxetumomab pasudotox-tdfk Intravenous-Dextran 70 6% in 5% Dextrose high molecular weight
- Moxetumomab pasudotox-tdfk Intravenous-Dextran 75
- Moxetumomab pasudotox-tdfk Intravenous-Dextran high molecular weight
- Moxetumomab pasudotox-tdfk Intravenous-Dextranomer and Hyaluronate Derivatives (Deflux)
- Moxetumomab pasudotox-tdfk Intravenous-Dextranomer and Hyaluronate Derivatives (Solesta)
- Moxetumomab pasudotox-tdfk Intravenous-Dextranomer and sodium hyaluronate